Actively Recruiting
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Led by University of Florida · Updated on 2026-05-05
50
Participants Needed
1
Research Sites
88 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.
CONDITIONS
Official Title
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients receiving cangrelor infusion at 0.75 mcg/kg/min for at least two hours as part of standard care
- Age 18 years or older
- Ability to provide written informed consent
You will not qualify if you...
- Need for urgent surgery
- Confirmed or suspected pregnancy or breastfeeding
- Use of oral P2Y12 inhibitors, oral anticoagulants, or glycoprotein IIb/IIIa inhibitors within 48 hours
- Known allergy or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Florida Jacksonville
Jacksonville, Florida, United States, 32209
Actively Recruiting
Research Team
L
Luis Ortega-Paz, MD, PhD
CONTACT
A
Andrea Burton, MPH, CCRP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here